UBS Sees 6-9% Growth for Amneal: Why the Recent Dip is a Buying Opportunity

UBS starts coverage on Amneal Pharmaceuticals with a Buy rating. Strong specialty growth, Parkinson’s drugs, and attractive entry point after recent selloff.